自体颊黏膜覆盖联合波士顿1型人工角膜用于严重眼表改变病例
回顾性介入病例系列纳入19眼(19例,平均年龄61±18岁)因不可逆角膜混浊行波士顿1型人工角膜联合自体口腔黏膜移植(B1KProM)。黏膜再上皮化中位时间3周,黏膜并发症见于9眼(47%)共14次、除2眼伴移植物排出外均成功处理;解剖失败4/19(21%)均为自身免疫病,12、24、36个月解剖成功率累积概率分别为89%、80%、40%。作者认为B1KProM是复杂眼表病变有前景的选择,黏膜并发症常见但可控,需进一步研究确认长期有效性。
要点
- 19眼中解剖失败4眼(21%),全部为自身免疫病患者。
- 12、24、36个月解剖成功率累积概率分别为89%、80%、40%。
- 有视觉潜力者中11/12眼(92%)术后某时点BCVA≥20/200。
核心结论
- B1KProM对于复杂眼表病变患者 seems 是有前景的选择,黏膜并发症常见但可控,需进一步研究确认其长期有效性。
研究设计与样本
- 回顾性介入病例系列,纳入19例患者19眼(12例男性,平均年龄61±18岁),均为不可逆角膜混浊(自身免疫病11眼、化学烧伤5眼、其他3眼),接受B1KProM手术。
主要发现
- 黏膜再上皮化中位时间为3周。
- 黏膜并发症为上皮化不良、黏膜过度生长和坏死,发生于9眼(47%)共14次,除2眼伴移植物排出外均成功处理。
- 其他并发症发生率低于既往报道范围。
- 解剖失败4/19(21%),全部为自身免疫病患者;12、24、36个月解剖成功累积概率分别为89%、80%、40%。
- 有视觉潜力的12眼中11眼(92%)术后某时点BCVA≥20/200;12、24、36个月功能成功累积概率分别为89%、78%、29%;平均随访18±12个月(范围1-36个月)。
关键数值与推荐
- 解剖成功定义为随访期间人工角膜留存;功能成功定义为末次随访时术后最佳矫正视力(BCVA)≤1.3 logMAR。
局限性
- 原文结论指出需进一步研究以确认其长期有效性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To evaluate anatomical and functional outcomes, and complications, of Boston type 1 keratoprosthesis with autologous oral mucosa graft (B1KProM) to reconstruct and protect the ocular surface of eyes with severe conditions. DESIGN: Retrospective interventional case series. METHODS: Data from 19 eyes of 19 patients (12 males; mean age of 61 ± 18 years) with irreversible corneal opacification (autoimmune diseases [11], chemical burns [5], or other [3]), who underwent B1KProM surgery. Anatomical success was defined as retention of the keratoprosthesis during the follow-up and functional success as postoperative best-corrected visual acuity (BCVA) ≤1.3 logMAR at the last follow-up. RESULTS: The median mucosal reepithelialization time was 3 weeks. Mucosal complications were poor epithelization, overgrowth, and necrosis and occurred in 14 episodes in 9 eyes (47%), all successfully managed, except in 2 eyes with concomitant extrusion. The incidence of other complications was under previously described ranges. Anatomical failure occurred in 4 of 19 cases (21%), all of them with autoimmune diseases. Cumulative probability of anatomical success was 89%, 80%, and 40% at 12, 24, and 36 months, respectively. BCVA ≥20/200 was found at some point postoperatively in 11 of 12 cases (92%) with visual potential. Cumulative probability of functional success was 89%, 78%, and 29% at 12, 24, and 36 months, respectively. The mean follow-up was of 18±12 months (range: 1-36 months). CONCLUSIONS: B1KProM emerges as a promising option for patients with complex ocular surface conditions. Mucosal complications were frequent but manageable. Further research is essential to confirm its long-term effectiveness.
引用
- Segura-Duch G, Martí-Orpinell M, Casado-López D, et al. Boston Type 1 Keratoprosthesis With Autologous Buccal Mucosa Overlay for Cases With Severe Ocular Surface Alterations. Am J Ophthalmol. 2025. PMID: 40669591. doi:10.1016/j.ajo.2025.07.011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。